SEC Form 4														
FORM 4 UNITED			STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							SION	OMB APPROVAL			
Check this box i Section 16. Forr obligations may Instruction 1(b).		• STAT	Filed pursuan	t to Section 16(a) c tion 30(h) of the Inv	of the Se	ecuritie	es Exchange A	Act of 193	_		MB Number: stimated average burd purs per response:	3235-0287		
1. Name and Address of Reporting Person <sup>*</sup> Nuechterlein Carole				2. Issuer Name and Ticker or Trading Symbol Aligos Therapeutics, Inc. [ ALGS ]						ationship of Repo k all applicable) Director	Reporting Person(s) to Issuer ble) 10% Owner			
(Last)	(First)	(Middle)								Officer (give ti below)	itle Other below	(specify )		
C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR				4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Indi Line)	,				
(Street) SOUTH SAN FRANCISCO	СА	94080	Rule	10b5-1(c) T	rans	acti	on Indica	tion		Form filed by Person	More than One Rep	orting		
(City)	(State)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							ed to			
		Table I - Non	-Derivative S	ecurities Acqu	uired,	Disp	posed of, o	or Bene	ficially	Owned				
Date			2. Transaction Date (Month/Day/Year)	Execution Date,		iction Instr.	4. Securities A Disposed Of ( 5)			5. Amount of Securities Beneficially Owned Followin	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
					Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	trivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$0.38	06/27/2024		A		60,000		(1)	06/27/2034	Common Stock	60,000	\$0	60,000	D	

Explanation of Responses:

1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2025 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.

/s/ Lesley Ann Calhoun, as	
attorney-in fact for Carole	06/28/2024
Nuechterlein	

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.